$TECX
Tectonic Therapeutic, Inc.

2022 Q1 Form 10-Q Financial Statement

#000156459022019306 Filed on May 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q4 2021 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.17M $8.962M $8.360M
YoY Change 21.59% 5.68% 0.48%
% of Gross Profit
Research & Development $19.25M $19.00M $18.53M
YoY Change 3.9% -3.01% 1.42%
% of Gross Profit
Depreciation & Amortization $399.0K $436.0K $291.0K
YoY Change 37.11% 40.65% 2.83%
% of Gross Profit
Operating Expenses $29.42M $27.96M $26.88M
YoY Change 9.43% -0.35% 1.11%
Operating Profit -$29.42M -$26.88M
YoY Change 9.43% 1.11%
Interest Expense -$370.0K -$265.0K -$20.00K
YoY Change 1750.0% 278.57% -103.23%
% of Operating Profit
Other Income/Expense, Net -$415.0K -$15.00K
YoY Change 2666.67% -102.44%
Pretax Income -$29.83M -$28.23M -$26.90M
YoY Change 10.9% 0.34% 3.58%
Income Tax
% Of Pretax Income
Net Earnings -$29.83M -$28.23M -$26.90M
YoY Change 10.91% 0.34% 3.57%
Net Earnings / Revenue
Basic Earnings Per Share -$0.68
Diluted Earnings Per Share -$682.8K -$646.6K -$646.3K
COMMON SHARES
Basic Shares Outstanding 43.70K 41.62M
Diluted Shares Outstanding 43.70K

Balance Sheet

Concept 2022 Q1 2021 Q4 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $161.7M $189.6M $233.0M
YoY Change -30.62% -27.01% -9.58%
Cash & Equivalents $161.7M $189.6M $233.0M
Short-Term Investments
Other Short-Term Assets $805.0K $1.698M $387.0K
YoY Change 108.01% 517.45% -59.94%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $170.9M $199.1M $242.1M
YoY Change -29.4% -25.48% -8.74%
LONG-TERM ASSETS
Property, Plant & Equipment $3.867M $4.126M $2.930M
YoY Change 31.98% 34.66% -13.82%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $555.0K $74.00K $900.0K
YoY Change -38.33% -83.03% -10.0%
Total Long-Term Assets $4.422M $4.692M $3.800M
YoY Change 16.37% 17.54% -13.64%
TOTAL ASSETS
Total Short-Term Assets $170.9M $199.1M $242.1M
Total Long-Term Assets $4.422M $4.692M $3.800M
Total Assets $175.3M $203.8M $245.9M
YoY Change -28.69% -24.85% -8.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.037M $3.486M $2.700M
YoY Change 49.52% 29.98% 28.57%
Accrued Expenses $12.88M $15.64M $9.822M
YoY Change 31.12% 14.2% 416.95%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $17.13M $19.39M $12.80M
YoY Change 33.83% 16.68% 0.0%
LONG-TERM LIABILITIES
Long-Term Debt $15.02M $14.95M $0.00
YoY Change
Other Long-Term Liabilities $30.00K $30.00K $200.0K
YoY Change -85.0% -90.0% -50.0%
Total Long-Term Liabilities $15.05M $14.98M $200.0K
YoY Change 7425.0% 4891.67% -50.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.13M $19.39M $12.80M
Total Long-Term Liabilities $15.05M $14.98M $200.0K
Total Liabilities $32.18M $34.36M $13.00M
YoY Change 147.54% 103.44% -1.52%
SHAREHOLDERS EQUITY
Retained Earnings -$413.4M -$383.5M -$291.3M
YoY Change 41.9% 45.05%
Common Stock $553.0M
YoY Change 6.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $143.2M $169.5M $232.9M
YoY Change
Total Liabilities & Shareholders Equity $175.3M $203.8M $245.9M
YoY Change -28.69% -24.85% -8.82%

Cashflow Statement

Concept 2022 Q1 2021 Q4 2021 Q1
OPERATING ACTIVITIES
Net Income -$29.83M -$28.23M -$26.90M
YoY Change 10.91% 0.34% 3.57%
Depreciation, Depletion And Amortization $399.0K $436.0K $291.0K
YoY Change 37.11% 40.65% 2.83%
Cash From Operating Activities -$28.01M -$25.90M -$27.34M
YoY Change 2.47% -15.04% 21.86%
INVESTING ACTIVITIES
Capital Expenditures $32.00K -$850.0K $115.0K
YoY Change -72.17% 962.5% -80.07%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$32.00K -$850.0K -$115.0K
YoY Change -72.17% 962.5% -80.07%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 142.0K 14.94M 799.0K
YoY Change -82.23% -78.86% -99.15%
NET CHANGE
Cash From Operating Activities -28.01M -25.90M -27.34M
Cash From Investing Activities -32.00K -850.0K -115.0K
Cash From Financing Activities 142.0K 14.94M 799.0K
Net Change In Cash -27.90M -11.80M -26.66M
YoY Change 4.69% -129.39% -137.73%
FREE CASH FLOW
Cash From Operating Activities -$28.01M -$25.90M -$27.34M
Capital Expenditures $32.00K -$850.0K $115.0K
Free Cash Flow -$28.05M -$25.05M -$27.45M
YoY Change 2.16% -17.61% 19.31%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Investment Income Net
InvestmentIncomeNet
-370000
CY2021Q1 us-gaap Investment Income Net
InvestmentIncomeNet
10000
CY2022Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
45000
CY2021Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
25000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-415000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-15000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-29833000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-26899000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29833000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26899000
CY2022Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.68
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.65
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
43695000
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
41618000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
254344000
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y9M14D
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y11M15D
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y9M10D
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4635000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
850000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
169476000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3378000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
142000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-29833000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
143163000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-29833000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-26899000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3378000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4635000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
399000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
291000
CY2022Q1 avro Non Cash Interest Expense
NonCashInterestExpense
75000
CY2022Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-9000
CY2022Q1 avro Deferred Rent Expense
DeferredRentExpense
-48000
CY2021Q1 avro Deferred Rent Expense
DeferredRentExpense
-52000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-320000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1477000
CY2022Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-11000
CY2021Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-10000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
551000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-26000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2876000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-3821000
CY2022Q1 us-gaap Long Term Notes Payable
LongTermNotesPayable
15020000
CY2021Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
14945000
CY2022Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
30000
CY2021Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
30000
CY2022Q1 us-gaap Liabilities
Liabilities
32180000
CY2021Q4 us-gaap Liabilities
Liabilities
34361000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43696000
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43696000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43652000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43652000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
29418000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
26884000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-29418000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-26884000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28014000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27339000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
32000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
115000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-32000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-115000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
850000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
142000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
799000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-27904000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-26655000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
190059000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
260174000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
162155000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
233519000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
117000
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
42000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
304000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
161663000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
233027000
CY2022Q1 us-gaap Restricted Cash
RestrictedCash
492000
CY2021Q1 us-gaap Restricted Cash
RestrictedCash
492000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
162155000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
233519000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-29833000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-413375000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
161663000
CY2022Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
112000
CY2022Q1 avro Prepaid Compensation Benefits
PrepaidCompensationBenefits
518000
CY2021Q4 avro Prepaid Compensation Benefits
PrepaidCompensationBenefits
575000
CY2022Q1 us-gaap Other Assets Current
OtherAssetsCurrent
805000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1698000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9258000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9578000
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires that the Company make estimates and judgments that may affect the reported amounts of assets, liabilities and expenses and the related disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. On an ongoing basis, the Company evaluates its estimates, judgments and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates. Changes in estimates are reflected in reported results in the period in which they become known.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant estimates relied upon in preparing the unaudited condensed consolidated financial statements include the determination of the fair value of share-based awards issued and the estimation of accrued research and development expenses. </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p>
CY2022Q1 avro Collaborative Agreement Expenses
CollaborativeAgreementExpenses
963000
CY2021Q1 avro Collaborative Agreement Expenses
CollaborativeAgreementExpenses
0
CY2022Q1 avro Fair Value Input Amount Transfer Between Levels
FairValueInputAmountTransferBetweenLevels
0
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12879000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15638000
CY2022Q1 avro Prepaid Research And Development Costs Current
PrepaidResearchAndDevelopmentCostsCurrent
4521000
CY2021Q4 avro Prepaid Research And Development Costs Current
PrepaidResearchAndDevelopmentCostsCurrent
4496000
CY2022Q1 avro Tax Incentive Refund Current
TaxIncentiveRefundCurrent
2844000
CY2021Q4 avro Tax Incentive Refund Current
TaxIncentiveRefundCurrent
2697000
CY2022Q1 us-gaap Prepaid Insurance
PrepaidInsurance
570000
CY2022Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8086000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7946000
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4219000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3820000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3867000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4126000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
399000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
291000
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
492000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
492000
CY2022Q1 avro Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
7396000
CY2021Q4 avro Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
8882000
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4325000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5579000
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
978000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
999000
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
180000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
178000
CY2022Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
16350000
CY2022Q1 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
1330000
CY2022Q1 us-gaap Long Term Notes Payable
LongTermNotesPayable
15020000
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
1875000
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
7500000
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
5625000
CY2022Q1 us-gaap Long Term Debt
LongTermDebt
15000000
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 avro Undesignated Preferred Stock
UndesignatedPreferredStock
10000000
CY2021Q4 avro Undesignated Preferred Stock
UndesignatedPreferredStock
10000000
CY2022Q1 avro Undesignated Shares Of Preferred Stock Outstanding
UndesignatedSharesOfPreferredStockOutstanding
0
CY2021Q4 avro Undesignated Shares Of Preferred Stock Outstanding
UndesignatedSharesOfPreferredStockOutstanding
0
CY2022Q1 us-gaap Dividends Cash
DividendsCash
0
CY2022Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
15924067
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
13808059
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0167
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0063
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8019
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8067
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7423777
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1469000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3125465
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.87
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1077937
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
13.38
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9471305
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.70
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
280000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3194119
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
13.27
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
280000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1729000
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.29
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.69
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
1000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
2000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4635000
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
34360000
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M10D
CY2022Q1 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.23

Files In Submission

Name View Source Status
0001564590-22-019306-index-headers.html Edgar Link pending
0001564590-22-019306-index.html Edgar Link pending
0001564590-22-019306.txt Edgar Link pending
0001564590-22-019306-xbrl.zip Edgar Link pending
avro-10q_20220331.htm Edgar Link pending
avro-10q_20220331_htm.xml Edgar Link completed
avro-20220331.xsd Edgar Link pending
avro-20220331_cal.xml Edgar Link unprocessable
avro-20220331_def.xml Edgar Link unprocessable
avro-20220331_lab.xml Edgar Link unprocessable
avro-20220331_pre.xml Edgar Link unprocessable
avro-ex101_29.htm Edgar Link pending
avro-ex311_7.htm Edgar Link pending
avro-ex312_8.htm Edgar Link pending
avro-ex321_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending